U. Chowdaiah (Mandya, IN)
Clearmedi Radiant Hospital Orthopaedic surgeryPresenter Of 1 Presentation
P201 - A Prospective Observational Study of Functional Outcome of Leucocyte Poor Platelet Rich Plasma Therapy for Bilateral Grade IV OA Knee.
Abstract
Purpose
To assess pain relief in patients with bilateral grade IV osteoarthritis knee by using visual analogue scale (VAS) system and functional outcome by Western Ontario and Mcmaster universities Arthritis index (WOMAC) in patients undergoing intra-articular autologous LP-PRP therapy. We have chosen LP-PRP therapy for Grade-IV Osteoarthritis knee to combat pain and disability to do activities of daily living. Our study included Patients who were not willing to undergo Total Knee Replacement (TKR) for various reasons.
Methods and Materials
A total number of 50 (n=50) patients who fulfilled the inclusion criteria were included to the study during the period of May 2019 to Jan 2020. Patients included were those who presented with bilateral grade IV OA knee. They were subjected to intra-articular autologous LP-PRP injection therapy to both the affected knees with an interval of 15 days. Post injection all patients were subjected to standard osteoarthritis rehabilitation protocol, pain relief was assessed by VAS system and functional outcome was assessed by WOMAC index at the end of 1st week, 2nd week, 1st month, 2nd month, 4th month,and 6th Month.
Results
The VAS score reflected highly significant improvement in the pain of the knee with a significant p value of < 0.001 and functional outcome was assessed by WOMAC index with a significant p value of < 0.001. It was noted that when the pre-procedure VAS score (mean VAS score 8.2) were compared with the score of most recent follow up i.e. at the end of 6th month (mean VAS score 1.4) shows a significant improvement in pain.
Conclusion
Intra-articular autologous LP-PRP injection therapy is a Good procedure of choice for treating patients with Grade-IV osteoarthritis knee for short period of time to combat pain and disability with a significant outcome in VAS score and WOMAC index in patients who were not willing for TKR.
Presenter Of 1 Presentation
P201 - A Prospective Observational Study of Functional Outcome of Leucocyte Poor Platelet Rich Plasma Therapy for Bilateral Grade IV OA Knee.
Abstract
Purpose
To assess pain relief in patients with bilateral grade IV osteoarthritis knee by using visual analogue scale (VAS) system and functional outcome by Western Ontario and Mcmaster universities Arthritis index (WOMAC) in patients undergoing intra-articular autologous LP-PRP therapy. We have chosen LP-PRP therapy for Grade-IV Osteoarthritis knee to combat pain and disability to do activities of daily living. Our study included Patients who were not willing to undergo Total Knee Replacement (TKR) for various reasons.
Methods and Materials
A total number of 50 (n=50) patients who fulfilled the inclusion criteria were included to the study during the period of May 2019 to Jan 2020. Patients included were those who presented with bilateral grade IV OA knee. They were subjected to intra-articular autologous LP-PRP injection therapy to both the affected knees with an interval of 15 days. Post injection all patients were subjected to standard osteoarthritis rehabilitation protocol, pain relief was assessed by VAS system and functional outcome was assessed by WOMAC index at the end of 1st week, 2nd week, 1st month, 2nd month, 4th month,and 6th Month.
Results
The VAS score reflected highly significant improvement in the pain of the knee with a significant p value of < 0.001 and functional outcome was assessed by WOMAC index with a significant p value of < 0.001. It was noted that when the pre-procedure VAS score (mean VAS score 8.2) were compared with the score of most recent follow up i.e. at the end of 6th month (mean VAS score 1.4) shows a significant improvement in pain.
Conclusion
Intra-articular autologous LP-PRP injection therapy is a Good procedure of choice for treating patients with Grade-IV osteoarthritis knee for short period of time to combat pain and disability with a significant outcome in VAS score and WOMAC index in patients who were not willing for TKR.